# US 2008/0287541 A1 · Kit for Treatment of Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287541 A1
- Document ID: US20080287541A1
- Status: Published application
- Kind: A1
- Application number: 11/596,043
- Filed: 2005-05-09
- Published: 2008-11-20
- Earliest claimed: 2004-05-10
- Assignees: Redoxia Israel Ltd.
- Inventors: Arnold Hoffman; Lee M. Spetner; Michael Burke
- Web page: https://patentgrep.com/patent/US20080287541A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- G08B 21/04: responsive to non-activity, e.g. of elderly persons (G08B21/06 takes precedence)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G08B: SIGNALLING SYSTEMS, e.g. PERSONAL CALLING SYSTEMS; ORDER TELEGRAPHS; ALARM SYSTEMS

## Abstract

The present invention relates to a kit for the treatment of cancer comprising (a) a container for containing a first compound (i) or a precursor thereof, said first compound or precursor being a compound that oxidizes glutathione (GSH); (b) a container for containing a second compound (ii) or a precursor thereof, said second compound or precursor being a compound that forms an adduct or conjugate with GSH; (c) a container for containing a third compound (iii) or a precursor thereof, said third compound or precursor being a compound that inhibits the rate-limiting enzyme of GSH biosynthesis, gamma-glutamylcysteine synthetase (GCS); and (d) a container for containing a fourth compound (iv) or a precursor thereof, said fourth compound or precursor being a compound that inhibits the enzyme responsible for the conversion of GSSG to GSH, glutathione reductase (GR).

## Claims

### Claim 1

A kit comprising:
(a) a container for containing a first compound (i) or a precursor thereof, said first compound or precursor being a compound that oxidizes glutathione (GSH);
(b) a container for containing a second compound (ii) or a precursor thereof, said second compound or precursor being a compound that forms an adduct or conjugate with GSH;
(c) a container for containing a third compound (iii) or a precursor thereof, said third compound or precursor being a compound that inhibits the rate-limiting enzyme of GSH biosynthesis, γ-glutamylcysteine synthetase (GCS);
(d) a container for containing a fourth compound (iv) or a precursor thereof, said fourth compound or precursor being a compound that inhibits the enzyme responsible for the conversion of GSSG to GSH, glutathione reductase (GR); and
instructions for administration of said four compounds for treatment of cancer.

### Claim 2 (depends on 1)

A kit according to claim 1 wherein:
said first compound (i) or precursor thereof is selected from the group consisting of disulfiram, diamide, diethylmalate, hydrogen peroxide precursors selected from the group consisting of ascorbic acid and dopamine, α-lipoic acid, oxidized low density lipoproteins (ox-LDLs), and a quinone selected from the group consisting of duroquinone, an ubiquinone, and β-lapachone;
said second compound (ii) or precursor thereof is selected from the group consisting of arsenic trioxide, ethacrynic acid, epothilones A and B, an α,β-unsaturated aldehyde or ketone, an unsubstituted or partially substituted quinone, an isoflavone, and a phenol;
said third compound (iii) is buthionine sulfoximine (BSO); and
said fourth compound (iv) is selected from the group consisting of 2-chloroethyl isocyanate, cyclohexyl isocyanate, 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU or carmustine), 1-(2-chloroethyl)-3-(cyclohexyl)-1-nitrosourea, 1-(2-chloroethyl)-3-(4-trans-methylcyclohexyl)-1-nitrosourea, and 1-(2-chloroethyl)-3-(trans-4-hydroxycyclohexyl)-1-nitrosourea, ofloxacin, levofloxacin, cefepime, and cefazolin.

### Claim 3 (depends on 2)

A kit according to claim 2 wherein said compound (ii) is selected from the group consisting of ethacrynic acid (EA); epothilone A and epothilone B; an α,β-unsaturated aldehyde such as cinnamaldehyde; a 4-hydroxyl-C5-C9-alkenal or a precursor thereof; a polyunsaturated fatty acid (PUFA); an unsubstituted or partially substituted quinone such as anthraquinone, benzoquinone, 2-methyl-benzoquinone, 2,6-dimethyl-benzoquinone, 2,5-dimethyl-benzoquinone, and 2,3,5-trimethyl-benzoquinone, □-tocopherolquinone and □-tocopherolquinone; an isoflavone such as catechin, daidzein, dicumarol, (−) epicatechin, flavopiridol, genistein, □-lapachone, myricetin and rotenone; and a phenol such as curcumin, yakuchinone A, yakuchinone B, (−) epigallocatechin-3-gallate, resveratrol, □-tocopherol, □-tocopherol, and arsenic trioxide.

### Claim 4 (depends on 3)

A kit according to claim 3 wherein said first compound (i) is disulfiram; said second compound (ii) is curcumin; said third compound (iii) is buthionine sulfoximine; and said fourth compound (iv) is carmustine.

### Claim 5

(canceled)

### Claim 6 (depends on 8)

A kit according to claim 8, wherein said cancer is leukemia or lymphoma.

### Claim 7 (depends on 8)

A kit according to claim 8, wherein said cancer is bladder, bone, brain, breast, cervical, colon, esophageal, kidney, laryngeal, liver, lung, melanoma, ovary, pancreas, prostate, rectal, skin, testicular, or uterine cancer.

### Claim 8 (depends on 1)

A kit according to claim 1, wherein said cancer is a primary tumor, a secondary tumor, or metastases thereof in the same organ or in another organ.

### Claim 9

A method of selectively inducing apoptosis in cancerous cells of a cancer patient, said method comprising administering to said cancer patient a pharmaceutically effective amount of a combination of 4 compounds effective to increase the redox potential of the cancerous cells to a threshold potential that induces apoptosis, while the increase in redox potential in non-cancerous cells does not induce apoptosis, wherein in said combination of 4 compounds each compound belongs to a different category selected from the group consisting of categories (i) to (iv):
(i) a compound, or a precursor thereof, that oxidizes GSH;
(ii) a compound, or a precursor thereof, that forms an adduct or a conjugate with GSH;
(iii) a compound, or a precursor thereof, that inhibits the rate-limiting enzyme of GSH biosynthesis, γ-glutamylcysteine synthetase (GCS); and
(iv) a compound, or a precursor thereof, that inhibits the enzyme responsible for the conversion of GSSG to GSH, glutathione reductase (GR).

### Claim 10 (depends on 9)

The method according to claim 9, wherein the redox potential of the cancerous cells is increased and maintained continuously in the range of about −200 to −180 mV for a time such as to achieve apoptosis in the cancerous cells.

### Claim 11 (depends on 9)

A method according to claim 9, wherein: said compound (i) or precursor thereof is selected from the group consisting of disulfiram, diamide, diethylmalate, hydrogen peroxide precursors selected from the group consisting of ascorbic acid and dopamine, α-lipoic acid, oxidized low density lipoproteins (ox-LDLs), and a quinone selected from the group consisting of duroquinone, an ubiquinone, and β-lapachone;
said compound (ii) or precursor thereof is selected from the group consisting of arsenic trioxide, ethacrynic acid, epothilones A and B, an α,β-unsaturated aldehyde or ketone, an unsubstituted or partially substituted quinone, an isoflavone, and a phenol;
said compound (iii) is buthionine sulfoximine (BSO); and
said compound (iv) is selected from the group consisting of 2-chloroethyl isocyanate, cyclohexyl isocyanate, 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU or carmustine), 1-(2-chloroethyl)-3-(cyclohexyl)-1-nitrosourea, 1-(2-chloroethyl)-3-(4-trans-methylcyclohexyl)-1-nitrosourea, and 1-(2-chloroethyl)-3-(trans-4-hydroxy-cyclohexyl)-1-nitrosourea, ofloxacin, levofloxacin, cefepime, and cefazolin.

### Claim 12 (depends on 11)

A method according to claim 11, wherein said compound (ii) is selected from the group consisting of ethacrynic acid (EA); epothilone A and epothilone B; an α,β-unsaturated aldehyde such as cinnamaldehyde; a 4-hydroxyl-C5-C9-alkenal or a precursor thereof; a polyunsaturated fatty acid (PUFA); an unsubstituted or partially substituted quinone such as anthraquinone, benzoquinone, 2-methyl-benzoquinone, 2,6-dimethyl-benzoquinone, 2,5-dimethyl-benzoquinone, and 2,3,5-trimethyl-benzoquinone, □-tocopherolquinone and □-tocopherolquinone; an isoflavone such as catechin, daidzein, dicumarol, (−) epicatechin, flavopiridol, genistein, □-lapachone, myricetin and rotenone; and a phenol such as curcumin, yakuchinone A, yakuchinone B, (−) epigallocatechin-3-gallate, resveratrol, □-tocopherol, □-tocopherol, and arsenic trioxide.

### Claim 13 (depends on 12)

A method according to claim 12, wherein said compound (i) is disulfiram; said compound (ii) is curcumin; said compound (iii) is buthionine sulfoximine; and said compound (iv) is carmustine.

### Claim 14 (depends on 9)

The method according to claim 9, wherein the cancer patient has a bladder, bone, brain, breast, cervical, colon, esophageal, kidney, laryngeal, liver, lung, melanoma, ovary, pancreas, prostate, rectal, skin, testicular, uterine cancer, leukemia or lymphoma.

### Claim 15

A method of selectively inducing apoptosis in cancerous cells of a cancer patient, said method comprising administering to said cancer patient pharmaceutically effective amount of a combination of 4 compounds effective to prevent phosphorylation of the retinoblastoma protein (pRB) in said cancerous cells, wherein in said combination of 4 compounds each compound belongs to a different category selected from the group consisting of categories (i) to (iv):
(i) a compound, or a precursor thereof, that oxidizes GSH;
(ii) a compound, or a precursor thereof, that forms an adduct or a conjugate with GSH;
(iii) a compound, or a precursor thereof, that inhibits the rate-limiting enzyme of GSH biosynthesis, γ-glutamylcysteine synthetase (GCS); and
(iv) a compound, or a precursor thereof, that inhibits the enzyme responsible for the conversion of GSSG to GSH, glutathione reductase (GR).

### Claim at position 16

16-19. (canceled)

### Claim 20

A method of selectively inducing apoptosis in cancerous cells of a cancer patient, said method comprising administering to said cancer patient pharmaceutically effective amount of a combination of 4 compounds effective to prevents release of transcriptional factors from the retinoblastoma protein (pRB) in said cancerous cells, wherein in said combination of 4 compounds each compound belongs to a different category selected from the group consisting of categories (i) to (iv):
(i) a compound, or a precursor thereof, that oxidizes GSH;
(ii) a compound, or a precursor thereof, that forms an adduct or a conjugate with GSH;
(iii) a compound, or a precursor thereof, that inhibits the rate-limiting enzyme of GSH biosynthesis, γ-glutamylcysteine synthetase (GCS); and
(iv) a compound, or a precursor thereof, that inhibits the enzyme responsible for the conversion of GSSG to GSH, glutathione reductase (GR).

### Claim at position 18

21-24. (canceled)

### Claim 25

A method of selectively inducing apoptosis in cancerous cells of a cancer patient, said method comprising administering to said cancer patient a pharmaceutically effective amount of a combination of 4 compounds such that the effect of the four compounds on the cancer cells continuously remain for the duration of time required to arrest the cancer cells in G1pm until apoptosis is induced whereas the normal cells in G1pm can enter G0 and remain unharmed, wherein each compound of the combination of 4 compounds belongs to a different category selected from the group consisting of categories (i) to (iv):
(i) a compound, or a precursor thereof, that oxidizes GSH;
(ii) a compound, or a precursor thereof, that forms an adduct or a conjugate with GSH;
(iii) a compound, or a precursor thereof, that inhibits the rate-limiting enzyme of GSH biosynthesis, γ-glutamylcysteine synthetase (GCS); and
(iv) a compound, or a precursor thereof, that inhibits the enzyme responsible for the conversion of GSSG to GSH, glutathione reductase (GR).

### Claim 26 (depends on 25)

The method of claim 25 wherein said duration of time corresponds to preferably 2-5 times the normal cell-cycle time.

### Claim 27 (depends on 26)

The method of claim 26 wherein said duration of time is from about 30 to about 250 hours.

### Claim 28

A method of selectively inducing apoptosis in cancerous cells of a cancer patient by decreasing the [GSH]2/[GSSG] ratio such that the redox potential E in said cancerous cells is increased to or above the threshold potential, while the increase in redox potential in non-cancerous cells is such that it remains below the threshold potential, said method comprising administering to said cancer patient a pharmaceutically effective amount of a combination of 4 compounds effective for decreasing the [GSH]2/[GSSG] ratio such that the redox potential E in said cancerous cells is increased to or above the threshold potential, wherein each compound belongs to a different category selected from the group consisting of categories (i) to (iv):
(i) a compound, or a precursor thereof, that oxidizes GSH;
(ii) a compound, or a precursor thereof, that forms an adduct or a conjugate with GSH;
(iii) a compound, or a precursor thereof, that inhibits the rate-limiting enzyme of GSH biosynthesis, γ-glutamylcysteine synthetase (GCS); and
(iv) a compound, or a precursor thereof, that inhibits the enzyme responsible for the conversion of GSSG to GSH, glutathione reductase (GR).

### Claim at position 23

29-39. (canceled)
